Viatris (VTRS) said Friday the phase 3 study evaluating the efficacy and safety of MR-139 ophthalmic ointment in subjects with blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.

The company said it is evaluating the next steps for the program, which may include a revision of the planned additional phase 3 study.

Viatris shares were down 3.5% in recent Friday premarket activity.